All the news Showing 10 of 102 articles from: Treatment for people living with HIV and HCVGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources 8-week course of Zepatier cures acute HCV in people with HIV Liz Highleyman / 05 April 2018 An 8-week course of grazoprevir/elbasvir (Zepatier) produced sustained virological response in most HIV-positive gay men with recent hepatitis C virus (HCV) genotype 1 or 4 infection, according to a presentation at the ... Hepatitis C treatment highly effective in harder-to-treat people with HIV co-infection, Spanish real-life study shows Michael Carter / 16 January 2018 Hepatitis C virus (HCV) treatment using direct-acting antivirals (DAAs) is highly effective and safe in harder-to-treat people with HIV co-infection, Spanish researchers report in AIDS. A sustained virological response (SVR), ... Hepatitis C test-and-treat programme reduces HCV by two-thirds among men who have sex with men in Swiss HIV Cohort Keith Alcorn / 31 October 2017 A systematic policy of test-and-treat cured 99% of men who have sex with men with hepatitis C in the Swiss HIV Cohort in an 8-month period and reduced the prevalence of hepatitis ... Gilead Sciences Announces FDA Approves Expanded Labeling for Epclusa Gilead press release / 02 August 2017 Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection Liz Highleyman / 26 July 2017 AbbVie's new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society ... Glecaprevir/pibrentasvir for hepatitis C can be safely administered with common antiretrovirals Liz Highleyman / 13 March 2017 AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for people with HIV/hepatitis C ... DAA therapy cures most people with HIV/HCV co-infection with decompensated cirrhosis or liver transplants Liz Highleyman / 07 March 2017 People with HIV/hepatitis C virus (HCV) co-infection with liver cirrhosis or liver failure, and those who received liver transplants, saw high rates of sustained virological response using interferon-free direct-acting antiviral (DAA) therapy for ... Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer? Liz Highleyman / 27 February 2017 People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular ... New hepatitis C infections among HIV-positive gay men drop by half after direct-acting antiviral roll-out in Netherlands Liz Highleyman / 17 February 2017 A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals for the treatment of hepatitis C, researchers have already seen a dramatic decline in acute ... Sofosbuvir/ledipasvir is effective for people with HIV/HCV co-infection in real-world clinical practice Liz Highleyman / 28 November 2016 The sofosbuvir/ledipasvir (Harvoni) co-formulation used in real-world clinical practice produced good sustained virological response rates similar to those seen in clinical trials for HIV-positive people with hepatitis C co-infection, according to a pooled ... ← Prev12345...11Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive